Isomorphic Labs Raises $5 Billion Six Months After $2.1 Billion Round
Isomorphic Labs, the Alphabet AI drug discovery company, has raised $5 billion, its second billion-dollar round in six months. It already received $2.1 billion in May 2026, bringing the total to $7.1 billion. The money will go into IsoDDE, a platform that predicts how a molecule binds to a protein, and into moving candidates into clinical trials. There is no approved drug yet, so investors are betting on the platform.
AI-processed from The Decoder; edited by Hamidun News
The most expensive bet on AI in medicine just got bigger. Isomorphic Labs, an Alphabet subsidiary that uses neural networks to search for new drugs, has announced a $5 billion round. This is already the second billion-dollar round in six months: in May 2026 the company raised $2.1 billion. Altogether that comes to about $7.1 billion in six months, and the company still has not a single approved drug.
Who invested and where the money will go
Greenoaks and Sequoia Capital led the round. They were joined by new investor Andreessen Horowitz, as well as Alphabet itself and all previous backers. The source does not disclose the company's valuation, so it is too early to discuss it.
The money will go to two things. The first is the company's own platform, IsoDDE (Isomorphic Drug Design Engine), a drug design engine. The second is advancing drug candidates toward clinical trials, that is, testing in humans. That is where most drugs fail, and no AI has yet eliminated that stage.
What IsoDDE is and how AlphaFold fits in
AlphaFold predicts a protein's shape from its amino acid sequence. For drug creation that is not enough: you need to understand how a small molecule will stick to a protein and at which exact site. It is like finding a key for a lock: you know the lock's shape, but the key has to fit precisely into the keyhole. According to the company, IsoDDE goes beyond AlphaFold 3 and better predicts this binding and where molecules sit. The source contains no independent comparisons, so this is Isomorphic's own claim.
The company was founded in 2021 and works with Novartis, Eli Lilly and Johnson & Johnson. It is led by Demis Hassabis. In August 2026 he stepped back from day-to-day leadership of Google DeepMind and became Alphabet's chief scientist. In 2024 he shared the Nobel Prize in Chemistry with John Jumper for work on AlphaFold.
Reshuffling inside Alphabet
The round comes amid personnel changes. The original AlphaFold team at DeepMind was disbanded in July 2026. Many researchers moved to Isomorphic Labs or other projects, and nearly a quarter left DeepMind entirely. DeepMind has not stopped, however: in early November it released AlphaGenome 2, a model that predicts how DNA variants affect gene activity in specific cell types.
The picture is this: Alphabet is spinning its applied drug work into a separate company and funding it heavily, while DeepMind keeps the foundational models for biology.
What this means for the industry
First, investors are willing to pay billions for an AI platform that has no product on the market yet. They are assessing how quickly the platform turns predictions into drug candidates. Second, leadership in "AI for science" is concentrating where there are strong teams, compute and ties to pharma. Small startups in this niche will find it increasingly hard to compete with budgets like these.
There are also honest limits. A drug's path from lab to approval takes years, and most candidates fail in clinical trials. Predicting how a molecule binds a protein is only part of the task. The molecule must then be safe, reach the right tissues and work in a living organism. Until Isomorphic shows a candidate in the clinic, the $7.1 billion remains a bet on potential.
For developers and founders the takeaway is simple. Vertical AI platforms in biotech are getting the largest checks, but they will be judged on clinical results, not on impressive model predictions. If you build tools for scientific teams, watch which drug development stages Isomorphic handles in-house and which it leaves to partners.
- Nov 21, 2026OpenAI Releases a Free CSAM Detector: It Flags 48% Fewer Images for the Same Findings
- Nov 21, 2026Dyania's AI on Nvidia Servers Reads Records of 7,800 Cleveland Clinic Patients
- Nov 21, 2026Claude Learned to Build Sites with Live Text Inside 3D Graphics in Chrome 157+
- Nov 21, 2026Anthropic Teaches Claude to Join Google Meet Calls and Take Notes
Key Questions Answered
Who invested and where the money will go?
Greenoaks and Sequoia Capital led the round. They were joined by new investor Andreessen Horowitz, as well as Alphabet itself and all previous backers. The source does not disclose the company's valuation, so it is too early to discuss it. The money will go to two things. The first is the company's own platform, IsoDDE (Isomorphic Drug Design Engine), a drug design engine. The second is advancing drug candidates toward clinical trials, that is, testing in humans.
What IsoDDE is and how AlphaFold fits in?
AlphaFold predicts a protein's shape from its amino acid sequence. For drug creation that is not enough: you need to understand how a small molecule will stick to a protein and at which exact site. It is like finding a key for a lock: you know the lock's shape, but the key has to fit precisely into the keyhole. According to the company, IsoDDE goes beyond AlphaFold 3 and better predicts this binding and where molecules sit. The source contains no independent comparisons, so this is Isomorphic's own claim.
What are the key details on Reshuffling inside Alphabet?
The round comes amid personnel changes. The original AlphaFold team at DeepMind was disbanded in July 2026. Many researchers moved to Isomorphic Labs or other projects, and nearly a quarter left DeepMind entirely. DeepMind has not stopped, however: in early November it released AlphaGenome 2, a model that predicts how DNA variants affect gene activity in specific cell types.
Ship AI Faster with Founders, Engineers & Weekly Architecture Reviews
Inside Vibe Club (hamidun.com/club) — weekly live masterminds with Zhemal Khamidun, Tech Radar, full LMS access, and 370+ production Claude Code skills.
The AI world, distilled — once a week
Seven stories that actually mattered, hand-picked. No noise, no reposts, no press releases.
Done! Check your inbox for a confirmation.